The ruling by a Missouri state court jury is a rare legal win for Abbott Laboratories, maker of Similac formula, and Reckitt, ...
The company denies the allegations. Earlier this year, the firm suffered a blow when a court ruled in March that it would ...
Abbott said in July it may have to pull Similac for premature infants off shelves if juries continue to side against ... The trial, which lasted more than a month, was the first time jurors weighed ...
The Whitfield family legal case was just one of many still pending relating to the necrotizing enterocolitis (NEC) disease.
Harvey Jones rejected any thought of buying this former FTSE 100 darling in August but after some positive news should he now revise his opinion? The post After jumping 10% this morning is this hated ...
"The decision reinforces what we, the medical community and regulatory bodies have said: that preterm infant nutrition products are safe," Abbott said in a statement. Mead Johnson said the verdict ...
was cleared of liability in a preterm formula case. “This feels like a big deal to us, putting a spoke in the wheels of what has hitherto been an unremittingly adverse narrative,” said RBC ...
In response, shares in Reckitt Benckiser soared 9.8% to 5,144.20 pence each in London early Friday. Reckitt was the best performing stock in the FTSE 100 index which was up 0.2%. Abbott Laboratories ...
LONDON (Reuters) - Shares in British consumer goods company Reckitt Benckiser jumped over 10% on Friday after the company, along with U.S.-based Abbott Labs, was cleared of liability in a preterm ...